See more : Sparinvest Japan Growth (SPIBJAKL.CO) Income Statement Analysis – Financial Results
Complete financial analysis of ShockWave Medical, Inc. (SWAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShockWave Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Atlas Copco AB (ACO1.F) Income Statement Analysis – Financial Results
- Continental Holdings Corporation (3703.TW) Income Statement Analysis – Financial Results
- Techpoint, Inc. (6697.T) Income Statement Analysis – Financial Results
- FastPassCorp A/S (FASTPC.CO) Income Statement Analysis – Financial Results
- American Lithium Corp. (LI.V) Income Statement Analysis – Financial Results
ShockWave Medical, Inc. (SWAV)
About ShockWave Medical, Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 730.23M | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M | 1.72M |
| Cost of Revenue | 95.39M | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M | 2.84M |
| Gross Profit | 634.84M | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M | -1.12M |
| Gross Profit Ratio | 86.94% | 86.73% | 82.53% | 69.03% | 60.03% | 40.88% | -64.98% |
| Research & Development | 145.65M | 81.68M | 50.54M | 36.93M | 32.85M | 22.70M | 17.96M |
| General & Administrative | 95.27M | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M | 5.42M |
| Selling & Marketing | 234.84M | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M | 6.36M |
| SG&A | 323.20M | 218.92M | 146.04M | 75.54M | 44.75M | 23.52M | 11.79M |
| Other Expenses | 23.96M | 1.06M | -582.00K | 1.26M | 2.35M | 589.00K | 366.00K |
| Operating Expenses | 468.85M | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M | 29.75M |
| Cost & Expenses | 564.24M | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M | 32.58M |
| Interest Income | 0.00 | 1.89M | 1.10M | 1.21M | 944.00K | 0.00 | 0.00 |
| Interest Expense | 6.20M | 1.89M | 1.10M | 1.21M | 944.00K | 401.00K | 58.00K |
| Depreciation & Amortization | 10.36M | -1.42M | -6.87M | 1.26M | 2.35M | 700.00K | 468.00K |
| EBITDA | 176.35M | 127.57M | -871.00K | -62.32M | -49.56M | -39.91M | -30.03M |
| EBITDA Ratio | 24.15% | 25.06% | -3.26% | -95.01% | -115.30% | -325.46% | -1,747.00% |
| Operating Income | 165.99M | 124.13M | -871.00K | -65.66M | -51.84M | -41.20M | -30.87M |
| Operating Income Ratio | 22.73% | 25.35% | -0.37% | -96.86% | -120.76% | -335.97% | -1,795.52% |
| Total Other Income/Expenses | 8.29M | -3.31M | -7.96M | 44.00K | 792.00K | 136.00K | 276.00K |
| Income Before Tax | 174.28M | 120.83M | -8.84M | -65.62M | -51.05M | -41.06M | -30.59M |
| Income Before Tax Ratio | 23.87% | 24.67% | -3.73% | -96.80% | -118.92% | -334.86% | -1,779.46% |
| Income Tax Expense | 27.00M | -95.17M | 301.00K | 80.00K | 62.00K | 38.00K | 26.00K |
| Net Income | 147.28M | 216.00M | -9.14M | -65.70M | -51.11M | -41.10M | -30.62M |
| Net Income Ratio | 20.17% | 44.10% | -3.85% | -96.92% | -119.06% | -335.17% | -1,780.98% |
| EPS | 4.01 | 6.02 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| EPS Diluted | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
| Weighted Avg Shares Out | 36.71M | 35.90M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
| Weighted Avg Shares Out (Dil) | 38.21M | 37.88M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week
A report surfaced that Johnson & Johnson was in talks to acquire Shockwave, though neither company has confirmed the rumors. An analyst initiated coverage on the stock.
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
Shockwave Medical rallies as J&J mulls purchase
Shockwave Medical shares are trading more than 3% higher in Wednesday's session, having soared more than 10% since it was announced Johnson & Johnson (NYSE:JNJ) was considering buying it. The maker of medical devices to treat heart diseases was reported...
Shockwave Medical shares rise on report of acquisition talks with Johnson & Johnson
Shares of medical-device maker Shockwave Medical Inc. rose Tuesday following a report that Johnson & Johnson was in talks to acquire the company.
Johnson & Johnson considers deal to buy Shockwave Medical, WSJ reports
Johnson & Johnson is in talks to buy medical device maker Shockwave Medical , the Wall Street Journal reported on Tuesday.
Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference
SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the...
3 Stocks That Could Create Lasting Generational Wealth
Shockwave Medical is in the early growth stages of bringing a disruptive medical device to market. Workday has industry-leading software that can transform it into a tech giant of the future.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Why Shockwave Medical Stands Out In The Medical Device Sector
Shockwave Medical specializes in developing and commercializing medical devices using IVL technology for treating calcified plaque in vascular and heart valve diseases. The company has achieved milestones such as obtaining reimbursement codes for coronary IVL procedures and EU MDR certification,...
Source: https://incomestatements.info
Category: Stock Reports